To enact section 3902.65 of the Revised Code regarding prescription drugs and medication switching under health benefit plans.
Impact
If enacted, SB160 will significantly alter statutory provisions concerning medication management under health insurance plans. By limiting the ability of insurers to adjust patient cost-sharing or change drug formulary placements without valid safety concerns raised by the FDA, the bill seeks to ensure that patients have consistent access to their prescribed medications. This measure may alleviate financial burdens on patients, allowing them to maintain their medication regimens without unexpected cost increases or removals.
Summary
Senate Bill 160 aims to regulate the policies surrounding prescription drugs and medication switching in Ohio. Specifically, the bill enacts section 3902.65 of the Revised Code, introducing stipulations for health plan issuers regarding the handling of medications. The legislation intends to protect patients from increased costs and restrict the removal of crucial medications from formularies unless certain FDA-related conditions are met. The core of the bill is about keeping essential medicines accessible and affordable to covered individuals under health benefit plans.
Sentiment
The general sentiment surrounding SB160 appears to lean towards supporting consumer protection in healthcare. Advocates for the bill argue that it safeguards individuals' rights to access medications without arbitrary restrictions or punitive costs imposed by insurance companies. However, there may be opposition from some insurers or healthcare providers who perceive the bill as limiting their flexibility in managing drug formularies and costs, which could necessitate broader operational adjustments.
Contention
A notable point of contention revolves around the balance of power between regulating health plans and enabling insurers to operate efficiently. Proponents emphasize the need for patient protection in healthcare coverage, while critics may argue that overly strict regulations could hinder insurers' ability to negotiate drug prices effectively or adapt to market changes. This reflects a broader debate about patient rights versus industry adaptability in the rapidly changing healthcare landscape.
To amend sections 3517.12, 3517.13, and 3517.155 of the Revised Code to modify the Campaign Finance Law regarding foreign nationals and statewide initiatives and referenda and to declare an emergency.
To amend sections 3517.12, 3517.13, and 3517.155 of the Revised Code to modify the Campaign Finance Law regarding foreign nationals and statewide initiatives and referenda and to declare an emergency.
To amend sections 3505.01 and 3505.10 of the Revised Code to modify the deadline for a political party to certify its nominees for President and Vice-President to the Secretary of State.
To delay the deadline for a major political party to certify its presidential and vice presidential candidates to the Secretary of State for the 2024 general election.